A wonderful business — priced for growth it hasn't delivered.

A great company, but no margin of safety at this price. Worth watching, not worth buying here.

Price $315.43 taken 2026-11-15 · market cap about $26B
Fair value $29 range $21 to $41 · from the FY25 annual report
Margin of safety −91%, above fair value no margin of safety · the price sits above fair value

The five checks

1 good · 2 caution · 2 warning

  • Warning
    Overvalued
    Fair value ~$29 vs $315 — trading 91% above what the math supports.
  • Warning
    Price assumes a big acceleration
    You'd need ~37%/yr free-cash-flow growth to justify today's price; it has done -25.2%/yr lately.
  • Good
    Revenue still growing
    Up 33.5% last year — demand isn't the problem.
  • Caution
    Cash flow flat-to-down
    Free cash flow ~-25.2%/yr — big, but not compounding. The crux for a value buyer.
  • Caution
    Manageable net debt
    Net debt of $0B — about 0.8× annual free cash flow. Normal for a mature company.

Price against fair value

What today's price assumes

Hold the price fixed and work backwards: how fast would free cash flow have to grow for $315 to make sense?

The price needs ~37% a year
Axon has delivered -25.2% a year over the last three years

Price assumes a big acceleration.

Where this number comes from →

How fair value is calculated

No analyst forecasts, no black box, no AI. Six lines from the filing to the answer.

  1. Free cash flow, typical yearThe five-year norm, from the annual reports$130M
  2. Ten years of it, growing 5% a year, each counted 9% lessThe same growth and discount for every company$1,064M
  3. Everything after year tenGrowing 2.5% a year, counted the same way+ $1,411M
  4. The business, in today's money$2,475M
  5. Subtract net debtBorrowings and finance leases less cash and securities− $100M
  6. Divide by the shares on file÷ 82.4M

Fair value per share$29

If our assumptions are wrong

Fair value per share under a faster or slower decade, and a gentler or harsher discount. The corners are where the $21 to $41 range comes from.

3% growth5% growth7% growth
8% discount$29$35$41
9% discount$25$29$34
10% discount$21$25$29

The blue cell is the published method. Every cell sits below today’s price.

Free cash flow, ten years

$ billions · Form 10-K

$0.0B FY16 $0.0B FY17 $0.1B FY18 $0.1B FY19 −$0.0B FY20 $0.1B FY21 $0.2B FY22 $0.1B FY23 $0.3B FY24 $0.1B FY25
  1. FY25 $0.1B
  2. FY24 $0.3B
  3. FY23 $0.1B
  4. FY22 $0.2B
  5. FY21 $0.1B
  6. FY20 −$0.0B
  7. FY19 $0.1B
  8. FY18 $0.1B
  9. FY17 $0.0B
  10. FY16 $0.0B

What the math is really telling you. Watch whether cash flow is compounding — that, more than any single year, is what a value read hangs on.

How this was built. Every figure is computed from Axon Enterprise, Inc.'s SEC filings — no estimates, no AI. Two-stage DCF: 9% discount rate, 5% free-cash-flow growth for 10 years, 2.5% terminal. Free cash flow is operating cash flow less capital spending. Fair value is based on typical free cash flow over the last five years ($0.1B), not the latest year ($0.1B), which sat 38% below the company's own norm. Net cash is cash and marketable securities less borrowings, commercial paper and finance leases; operating leases are disclosed but never counted as debt. Fundamentals are from the FY25 annual report and change only when a new one is filed. Price of $315.43 taken 2026-11-15 (Google Finance, manual entry, 2026-11-13) — it is not live and does not move during the day.

Read Axon another way

TickerMath is an educational tool, not investment advice — it computes one model from SEC filings and can be wrong. How we compute this →